Indonesia vs North Macedonia: Share of E. coli infections resistant to cephalosporins
Indonesia
69.7%
in 2022
North Macedonia
60.0%
in 2022
Indonesia rank
8th
North Macedonia rank
11th
Share of E. coli infections resistant to cephalosporins over time
- Indonesia
- North Macedonia
How they compare
Indonesia currently reports 69.7% against 60.0% in North Macedonia, a difference of 9.7%.
That makes Indonesia's figure about 1.2 times North Macedonia's.
The two have swapped places 3 times across 5 shared years of data; in 2018 it was North Macedonia ahead.
Indonesia ranks 8th and North Macedonia ranks 11th of 46 countries.
Across the 2 decades both report, Indonesia averaged higher in 1 and North Macedonia in 1.
Head to head by decade
| Decade | Indonesia | North Macedonia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 71.0% | 71.8% | 0.8% | North Macedonia |
| 2020s | 72.2% | 65.6% | 6.5% | Indonesia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Indonesia or North Macedonia?
- Indonesia, at 69.7% against 60.0% in North Macedonia as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Indonesia and North Macedonia?
- 9.7%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and North Macedonia?
- 5 years are reported by both, from 2018 to 2022.
- How do Indonesia and North Macedonia rank globally for share of e. coli infections resistant to cephalosporins?
- Indonesia ranks 8th and North Macedonia ranks 11th of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).